A novel set of S16020 derivatives was designed applying structure activity relationships (SAR). The newly synthesized compounds were subjected to in vitro cytostatic activity screening against human kidney cancer (cell line A498), human lung cancer (cell line A549) and normal human dermal fibroblasts (cell line NHDF). Two 6H-pyrido[4,3-b]carbazole derivatives exhibited stronger potency against both investigated cell lines than the reference compounds ellipticine and doxorubicin.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.